Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/toxins8050137 http://scihub22266oqcxt.onion/10.3390/toxins8050137 C4885052!4885052!27153091     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Toxins+(Basel) 2016 ; 8 (5): ä Nephropedia Template TP {{tp|p=27153091|t=2016. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers |pdf=|usr=}}{{27153091}} gab.com Text Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers JO: Toxins (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=27153091 #FOAvip Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have been approved for human use. However, many of the current small molecule or antibody-based therapeutics are of limited effectiveness due to the inevitable development of resistance and toxicity to normal tissues. Recombinant immunotoxins are therapeutic molecules consisting of an antibody or receptor ligand joined to a protein cytotoxin, combining the specific targeting of a cancer-expressed receptor with the potent cell killing of cytotoxic enzymes. Over the decades, many bacterial- or plant-based immunotoxins have been developed with the goal of targeting the broad range of cancers reliant upon EGFR overexpression. Many examples demonstrate excellent anti-cancer properties in preclinical development, and several EGFR-targeted immunotoxins have progressed to human trials. This review summarizes much of the past and current work in the development of immunotoxins for targeting EGFR-driven cancers. Twit Text FOAVip Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers ????Toxins (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=27153091 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27153091 #FOAvip English Wikipedia <ref>{{Cite pmid|27153091}}</ref> Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers #MMPMID27153091 Simon N; FitzGerald D Toxins (Basel) 2016[May]; 8 (5): ä PMID27153091show ga Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have been approved for human use. However, many of the current small molecule or antibody-based therapeutics are of limited effectiveness due to the inevitable development of resistance and toxicity to normal tissues. Recombinant immunotoxins are therapeutic molecules consisting of an antibody or receptor ligand joined to a protein cytotoxin, combining the specific targeting of a cancer-expressed receptor with the potent cell killing of cytotoxic enzymes. Over the decades, many bacterial- or plant-based immunotoxins have been developed with the goal of targeting the broad range of cancers reliant upon EGFR overexpression. Many examples demonstrate excellent anti-cancer properties in preclinical development, and several EGFR-targeted immunotoxins have progressed to human trials. This review summarizes much of the past and current work in the development of immunotoxins for targeting EGFR-driven cancers. äImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Rec(epmc).pdf DeepDyve Pubget Overpricing